Alexion Pharmaceuticals a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company was founded in 1992 and is based in Cheshire, Connecticut.
ALXN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Alexion Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Alexion Pharmaceuticals Inc ranked in the 73th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 236.67%. In terms of the factors that were most noteworthy in this DCF analysis for ALXN, they are:
The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than merely 20.88% of the free cash flow producing stocks we're observing.
ALXN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 41.52% of tickers in our DCF set.
As a business, Alexion Pharmaceuticals Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than merely 0% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ALXN, try PCRX, CI, INVA, SEM, and LXRX.
Alexion Pharmaceuticals (ALXN) has completed its acquisition of Portola Pharmaceuticals (PTLA), through a tender offer and merger with its subsidiary, Odyssey Merger Sub Inc. (“Buyer”).The acquisition adds Factor Xa inhibitor reversal agent Andexxa, marketed as Ondexxya in Europe, to Alexion’s commercial portfolio. Portola will cease to be traded on the Nasdaq and...
Alexion Pharmaceuticals Inc will pay nearly $21.5 million to resolve claims it improperly paid Turkish and Russian officials to secure favorable treatment for its main drug, Soliris, the U.S. Securities and Exchange Commission said Thursday.
Shares of Alexion Pharmaceuticals Inc. were up 0.1% in trading on Thursday after the Securities and Exchange Commission said the drugmaker would pay more than $21 million to resolve charges that it paid officials in Russian and Turkey to promise its immunosuppressive drug Soliris. The company allegedly paid government officials between 2010 and 2015 to encourage prescriptions of Soliris and secure "favorable regulatory treatment" for the drug. There are also allegations that subsidiaries in Brazil and Colombia failed to main accurate records. Alexion did not admit fault or deny the SEC's findings. Soliris is Alexion's top-selling drug, bringing in about $3.9 billion in sales in 2019. Alexion's stock has gained 3.9% year-to-date, while the S&P 500 is down 3.5%.